- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
The post Comparative and combined effects of seralutinib and nintedanib suggest synergistic anti-fibrotic and anti-inflammatory activity in IPF patient-derived lung models appeared first on Gossamer Bio.
The post Exploratory analysis of a PDGFRB protein quantitative trait locus and seralutinib treatment response in the phase 3 PROSERA PAH study appeared first on Gossamer Bio.
The post Targeted genetic profiling of PAH-predisposing genes and exploratory seralutinib response by genotype in the phase 3 PROSERA study appeared first on Gossamer Bio.
The post Effects of seralutinib on pulmonary vascular remodeling assessed by quantitative CT: A randomized, double-blind, placebo-controlled imaging substudy of the phase 3 PROSERA trial appeared first on Gossamer Bio.
The post Circulating biomarker results from a phase 2 study of seralutinib in pulmonary arterial hypertension appeared first on Gossamer Bio.
The post For Patients: Seralutinib for the Treatment of Pulmonary Arterial Hypertension: Results From the Phase 3 PROSERA Trial appeared first on Gossamer Bio.
The post Advancing Careers and Leadership in Pulmonary Hypertension: Key Insights From Pulmonary Hypertension Clinicians appeared first on Gossamer Bio.
The post Examining Undertreatment and Delays in Therapy for Pulmonary Arterial Hypertension: A Real-world Patient Journey Study from the US appeared first on Gossamer Bio.
The post Understanding Patient Experiences, Challenges, and Emotions During Diagnosis of PH-ILD: A Qualitative Study appeared first on Gossamer Bio.
The post Understanding the Diagnostic Journey of Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD): A Retrospective U.S. Claims Analysis appeared first on Gossamer Bio.